Potential use of psilocybin drugs in the treatment of depression

References

• American psychiatric Association Diagnostic and statistical manual of mental disorders. 5th. WA (DC): 2013; doi: 10.1176/appi.books.9780890425596
   Google Scholar
• National Institute of Health Care and Excellence (NICE). Depression in adults: treatment and management. Guideline 2022. (NG222).
   Google Scholar
• Li Z, Ruan M, Chen J, et al. Major depressive disorder: advances in neuroscience research and translational applications. Neurosci Bull. 2021;37(6):863–880. doi: 10.1007/s12264-021-00638-3
   PubMed Web of Science ®Google Scholar
• Dong JY, Zhang YH, Tong J, et al. Depression and risk of stroke. A meta-analysis of prospective studies. Stroke. 2012;43(1):32–37. doi: 10.1161/STROKEAHA.111.630871
   PubMed Web of Science ®Google Scholar
• Mattina GF, Van Lieshout RJ, Steiner M. Inflammation, depression and cardiovascular disease in women: the role of the immune system across critical reproductive events. Ther Adv Cardiovasc Dis. 2019;13:1753944719851950. doi: 10.1177/1753944719851950
   Google Scholar
• Wang YH, Li JQ, Shi JF. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487–1499. doi: 10.1038/s41380-019-0595-x
   PubMed Web of Science ®Google Scholar
• Andersson NW, Goodwin RD, Okkels N, et al. Depression and the risk of severe infections: prospective analyses on a nationwide representative sample. Int J Epidemiol. 2016;45(1):131–139. doi: 10.1093/ije/dyv333
   PubMed Web of Science ®Google Scholar
• Institute of Health Metrics and Evaluation [Internet]. Global Health data exchange (GHDx). [cited 2023 May 19]. Available from: https://vizhub.healthdata.org/gbd-results/
   Google Scholar
• World Health Organization (WHO) [Internet] Depressive disorder (depression). [cited 2023 May 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression
   Google Scholar
• Eurostat [Internet]. European Union. [cited 2023 May 19]. Available from: https://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20210910-1
   Google Scholar
• National Institute of Mental Health [Internet]. Statistics - major depression. [cited 2023 May 19]. Available from: https://www.nimh.nih.gov/health/statistics/major-depression
   Google Scholar
• Schlax J, Jünger C, Beutel ME, et al. Income and education predict elevated depressive symptoms in the general population: results from the Gutenberg health study. BMC Public Health. 2019;19(1):430. doi: 10.1186/s12889-019-6730-4
   PubMed Web of Science ®Google Scholar
• Lorant V, Croux C, Weich S, et al. Depression and socio-economic risk factors: 7-year longitudinal population study. Br J Psychiatry. 2007;90(4):293–298. doi: 10.1192/bjp.bp.105.020040
   Google Scholar
• WHO [Internet]. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression wordwide. [cited 2023 May 19]. Available from: https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide
   Google Scholar
• American Psychological Association. APA clinical practice guideline for the treatment of depression across three age cohorts. Feb 2019. https://www.apa.org/depression-guideline
   Google Scholar
• Bennabi D, Charpeaud T, Yrondi A, et al. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry. 2019;19(1)262. doi: 10.1186/s12888-019-2237-x
   PubMed Web of Science ®Google Scholar
• McIntyre MS. Targeting unmet needs in the treatment of major depressive disorder. Curr Psychiatry. 2019;18(9):supl. S1–S4.
   Google Scholar
• Braund TA, Tillman G, Palmer DM, et al. Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. Transl Psychiatry. 2021;11(1):417. doi: 10.1038/s41398-021-01533-1
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikuta T, Sakuma K, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023;28(1):402–409. doi: 10.1038/s41380-022-01824-z
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa T, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–1366. doi: 10.1016/S0140-6736(17)32802-7
   PubMed Web of Science ®Google Scholar
• Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290. doi: 10.7573/dic.212290
   PubMedGoogle Scholar
• Wang SM, Han C, Bahk WM, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101–112. doi: 10.4068/cmj.2018.54.2.101
   PubMedGoogle Scholar
• Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology. 2004;25(1–2):215–221. doi: 10.1016/S0161-813X(03)00097-4
   PubMed Web of Science ®Google Scholar
• Pilc A, Machaczka A, Kawalec P, et al. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opin Drug Discov. 2022;17(10):1131–1146. doi: 10.1080/17460441.2022.2111415
   PubMed Web of Science ®Google Scholar
• Brown RT, Nicholas CR, Cozzi NV, et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. 2017;56(12):1543–1554. doi: 10.1007/s40262-017-0540-6
   PubMed Web of Science ®Google Scholar
• Dydak K, Śliwińska-Mossoń M, Milnerowicz H. Psilocybin – public available psychodysleptic. Postepy Higieny i Medycyny Doswiadczalnej. 2015;69:986–995.
   Web of Science ®Google Scholar
• Lowe H, Toyand N, Steele B, et al. The therapeutic potential of psilocybin. Molecules. 2021;6(10):2948. doi: 10.3390/molecules26102948
   Google Scholar
• Grob CS, Bossis AP. Griffiths RR. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. In: Carr BSJ STEEL J, editors. Psychological aspects of cancer. Boston (MA): Springer; 2013. p. 291–308. doi: 10.1007/978-1-4614-4866-2_17
   Google Scholar
• McCulloch DE, Madsen MK, Jensen PS, et al. Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report. Front Pharmacol. 2022;13: doi: 10.3389/fphar.2022.841648
   PubMed Web of Science ®Google Scholar
• Smausz R, Neill J, Gigg J. Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology. J Psychopharmacol. 2022;36(7):781–793. doi: 10.1177/02698811221092508
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Lo LA, Pistawka CA, et al. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217. doi: 10.3389/fpsyt.2022.1040217
   PubMed Web of Science ®Google Scholar
• Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2014;78(8):1–9. doi: 10.1016/j.biopsych.2014.04.010
   Web of Science ®Google Scholar
• Kraehenmann R, Schmidt A, Friston K, et al. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin. 2015;11:53–60. doi: 10.1016/j.nicl.2015.08.009
   PubMed Web of Science ®Google Scholar
• Breckenridge A, Grobbee DE. Psilocybin: promising results in double-blind trials require confirmation by real-world evidence. J Psychopharmacol. 2016;30(12):1218–1219. doi: 10.1177/0269881116675784
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. doi: 10.1056/NEJMoa2206443
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life. J Affect Disord. 2023;327:120–127. doi: 10.1016/j.jad.2023.01.108
   PubMed Web of Science ®Google Scholar
• Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. doi: 10.1056/NEJMoa2032994
   PubMed Web of Science ®Google Scholar
• Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844–851. doi: 10.1038/s41591-022-01744-z
   PubMed Web of Science ®Google Scholar
• Davis AK, Barrett FS, May D, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. doi: 10.1001/jamapsychiatry.2020.3285
   PubMed Web of Science ®Google Scholar
• Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151–158. doi: 10.1177/02698811211073759
   PubMed Web of Science ®Google Scholar
• Doss MK, Považan M, Rosenberg MD, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translat Psychiatry. 2021;11(1):574. doi: 10.1038/s41398-021-01706-y
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. doi: 10.1001/archgenpsychiatry.2010.116
   PubMed Web of Science ®Google Scholar
• von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2023;56:101809. doi: 10.1016/j.eclinm.2022.101809
   PubMedGoogle Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. doi: 10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. doi: 10.1177/0269881116675512
   PubMed Web of Science ®Google Scholar
• Ross S, Agin-Liebes G, Lo S, et al. Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. ACS Pharmacol Transl Sci. 2021;4(2):553–562. doi: 10.1021/acsptsci.1c00020
   PubMedGoogle Scholar
• Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155–166. doi: 10.1177/0269881119897615
   PubMed Web of Science ®Google Scholar
• Hengartner MP, Plöderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid Based Med. 2022;27(2):69–73. doi: 10.1136/bmjebm-2020-111600
   PubMedGoogle Scholar
• Marschall J, Fejer G, Lempe P, et al. Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study. J Psychopharmacol. 2022;36(1):97–113. doi: 10.1177/02698811211050556
   PubMed Web of Science ®Google Scholar
• Ryan KM, Allers KA, Harkin S, et al. Blood plasma B vitamins in depression and the therapeutic response to electroconvulsive therapy. Brain Behav Immun Health. 2020;4:100063. doi: 10.1016/j.bbih.2020.100063
   PubMedGoogle Scholar
• Nguyen HD, Oh H, Kim MS. Mixtures modeling identifies vitamin B1 and B3 intakes associated with depression. J Affect Disord. 2022;301:68–80. doi: 10.1016/j.jad.2021.12.133
   PubMed Web of Science ®Google Scholar
• Roscoe J, Lozy O. Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials. Drug Sci Policy Law. 2022 8;8:205032452210852. doi: 10.1177/20503245221085222
   Google Scholar
• van der Meer PB, Fuentes JJ, Kaptein A, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023;14:1134454. doi: 10.3389/fpsyt.2023.1134454
   PubMed Web of Science ®Google Scholar
• Orsolini L, Valchera A, Papanti D, et al. The “endless trip”: psychopathology and psychopharmacology in the hallucinogen persisting perception disorder (HPPD). Eur Psychiatry. 2016;33(SUPPL):S310. doi: 10.1016/j.eurpsy.2016.01.1060
   Google Scholar
• Jo WS, Hossain A, Park SC. Toxicological profiles of poisonous, edible, and medicinal mushrooms. Mycobiology. 2014;42(3):215–220. doi: 10.5941/MYCO.2014.42.3.215
   PubMed Web of Science ®Google Scholar
• Satora L, Goszcz H, Ciszowski K. Poisonings resulting from the ingestion of magic mushrooms in Kraków. Przegl Lek. 2005;62(6):394–396.
   PubMedGoogle Scholar
• Leonard JB, Anderson B, Klein-Schwartz W, et al. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. J Psychopharmacol. 2018;32(12):1286–1294. doi: 10.1177/0269881118793086
   PubMed Web of Science ®Google Scholar
• Leger EF, Unterwald EM. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis. J Psychopharmacol. 2022;36(1):20–30. doi: 10.1177/02698811211044688
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Nutt DJ. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Subst Use. 2010;15(4):283–300. doi: 10.3109/14659890903271624
   Web of Science ®Google Scholar
• Levin A, Nagib PB, Deiparine S, et al. Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. Int J Drug Policy. 2022;108:103816. doi: 10.1016/j.drugpo.2022.103816
   PubMed Web of Science ®Google Scholar
• Nutt D, King LA, Phillips LD, et al. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558–1565. doi: 10.1016/S0140-6736(10)61462-6
   PubMed Web of Science ®Google Scholar
• Geiger HA, Wurst MG, Daniels RN. DARK classics in chemical neuroscience: psilocybin. ACS Chem Neurosci. 2018;9(10):2438–2447. doi: 10.1021/acschemneuro.8b00186
   PubMed Web of Science ®Google Scholar
• Jones GM, Nock MK. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol. 2022;36(1):57–65. doi: 10.1177/02698811211066714
   PubMed Web of Science ®Google Scholar
• Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268–1278. doi: 10.1177/0269881116662634
   PubMed Web of Science ®Google Scholar
• Australian Government [Internet]. Department of Health and aged care, therapeutic goods administration. [cited 2023 May 19]. Available from: https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma/re-scheduling-psilocybin-and-mdma-poisons-standard-questions-and-answers
   Google Scholar
• Australian Government [Internet]. Department of Health and aged care, therapeutic goods administration. [cited 2023 May 19]. Available from: https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
   Google Scholar
• Medscape [Internet]. News & perspective. [cited 2023 May 19]. Available from: https://www.medscape.com/viewarticle/921789/
   Google Scholar
• Public Health Division. Center for Health Protection [Internet]. Oregon psilocybin services. [cited 2023 May 19]. Available from: https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/2022-Year-in-Review.pdf and https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx
   Google Scholar
• American Psychiatric Association [Internet]. Position statement on the use of psychedelic and Empathogenic Agents for Mental Health Conditions. 2022. [cited 2023 May 19]. Available from: https://www.psychiatry.org/getattachment/d5c13619-ca1f-491f-a7a8-b7141c800904/Position-Use-of-Psychedelic-Empathogenic-Agents.pdf
   Google Scholar
• European Medicines Agency [Internet]. Re: on substances with psychedelic properties. Mar 2023. [cited 2023 May 19]. Available from: https://www.ema.europa.eu/en/documents/other/ema-reply-letter-members-european-parliament-mr-agius-saliba-ms-ries-mr-duda-mr-biedron-ms-cerdas-ms_en.pdf
   Google Scholar